Co-Diagnostics, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Co-Diagnostics, Inc. (CODX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax of -$418.44 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax · last filed 2026-08-13
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2025-12-31 was -$94.89K, a 1041.63% decline year-over-year.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2025-09-30 was -$39.18K, a 205.44% decline year-over-year.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2025-06-30 was -$196.59K, a 235.90% decline year-over-year.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2025-03-31 was -$87.79K, a 209.94% decline year-over-year.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2025 was -$418.44K, a 253.98% decline from fiscal 2024.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2024 was $271.74K.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2023 was -$146.44K, a 149.96% decline from fiscal 2022.
- Co-Diagnostics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2022 was $293.14K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$94.89K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$134.07K derived: sum of 2 quarters · filed 2026-03-31 | -$330.65K derived: sum of 3 quarters · filed 2026-08-13 | -$418.44K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$39.18K 10-Q · filed 2025-11-13 | -$235.76K derived: sum of 2 quarters · filed 2026-08-13 | -$323.56K 10-Q · filed 2025-11-13 | -$313.48K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$196.59K 10-Q · filed 2026-08-13 | -$284.38K 10-Q · filed 2026-08-13 | -$274.30K derived: sum of 3 quarters · filed 2026-08-13 | -$237.14K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$87.79K 10-Q · filed 2026-05-14 | -$77.71K derived: sum of 2 quarters · filed 2026-05-14 | -$40.55K derived: sum of 3 quarters · filed 2026-05-14 | $104.10K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $10.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $47.23K derived: sum of 2 quarters · filed 2026-03-31 | $191.89K derived: sum of 3 quarters · filed 2026-03-31 | $271.74K 10-K · filed 2026-03-31 |
| 2024-09-30 | $37.16K 10-Q · filed 2025-11-13 | $181.81K derived: sum of 2 quarters · filed 2025-11-13 | $261.67K 10-Q · filed 2025-11-13 | -$204.28K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $144.65K 10-Q · filed 2025-08-14 | $224.51K 10-Q · filed 2025-08-14 | -$241.44K derived: sum of 3 quarters · filed 2025-08-14 | -$207.92K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $79.86K 10-Q · filed 2025-05-08 | -$386.09K derived: sum of 2 quarters · filed 2025-05-08 | -$352.57K derived: sum of 3 quarters · filed 2025-05-08 | -$245.21K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$465.95K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$432.43K derived: sum of 2 quarters · filed 2025-03-27 | -$325.06K derived: sum of 3 quarters · filed 2025-03-27 | -$146.44K 10-K · filed 2025-03-27 |
| 2023-09-30 | $33.52K 10-Q · filed 2024-11-07 | $140.89K derived: sum of 2 quarters · filed 2024-11-07 | $319.51K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $107.37K 10-Q · filed 2024-08-08 | $285.99K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $178.62K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $293.14K 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |